Paolini John F. 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Apr 3, 2026

AI-generated summary of this filing

Updated Apr 3, 2026

Kiniksa (KNSA) CMO John Paolini Exercises Options, Receives Awards

What Happened

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), reported multiple equity-related transactions on April 1, 2026. He exercised/conversed derivatives (options) and received new equity awards (RSUs/PSUs). As part of the settlement, 2,821 shares were surrendered/withheld to cover tax liability at $48.13 per share, totaling $135,775.
Reported items include: exercise/conversion of 5,831 derivative shares (acquired), three award grants totaling 46,850 derivative units (26,750 + 6,700 + 13,400 RSU/PSU-type awards, reported at $0.00), and several small derivative settlements (1,624; 1,750; 2,457 shares) shown as disposed/zero-dollar in the filing. The tax withholding/surrender is coded F; exercises/conversions are coded M; grants/awards are coded A.

Key Details

Transaction date: April 1, 2026; Form filed April 3, 2026 (appears timely).
Tax withholding/surrender: 2,821 shares at $48.13 = $135,775 (code F).
Grants/Awards: three awards totaling 46,850 RSU/PSU-type units reported at $0.00 (code A).
Exercises/Conversions: multiple M-coded entries (5,831 acquired; several disposals of 1,624 / 1,750 / 2,457 shares shown at $0.00).
Shares owned after transaction: not specified in the provided filing excerpt.
Relevant footnotes: RSUs convert to one Class A ordinary share (F1); options/awards have multi-year vesting schedules with vesting commencement dates (notably April 1, 2026 for one grant) and some PSUs may convert up to 200% of one share based on performance through Jan 30, 2029.

Context

These transactions are largely compensation-related (awards and option exercises) rather than open-market purchases or sales by the officer. The surrender/withholding of 2,821 shares to cover taxes is a common cashless/net settlement practice when options or RSUs vest/are exercised.
PSUs are performance-based and may pay out between 0–200% of underlying shares depending on achievement of metrics (per footnote). RSUs generally vest over four years per the footnotes cited.
No indication in the filing excerpt that this was a 10% owner transaction or a gift; the activity looks like routine executive compensation settlement, not an open-market buy or sell.

Form 4

Period: 2026-04-01

CHIEF MEDICAL OFFICER

Transactions

Exercise/Conversion
Class A Ordinary Share
[F1]
2026-04-01+5,831→ 67,155 total
Tax Payment
Class A Ordinary Share
2026-04-01$48.13/sh−2,821$135,775→ 64,334 total
Award
Share Option
[F2]
2026-04-01+26,750→ 26,750 total
Exercise: $48.13Exp: 2036-03-31→ Class A Ordinary Share (26,750 underlying)
Award
Restricted Share Unit
[F1][F3]
2026-04-01+6,700→ 6,700 total
→ Class A Ordinary Share (6,700 underlying)
Award
Performance Share Unit
[F4][F5]
2026-04-01+13,400→ 13,400 total
→ Class A Ordinary Share (13,400 underlying)
Exercise/Conversion
Restricted Share Unit
[F1][F6]
2026-04-01−1,624→ 1,624 total
→ Class A Ordinary Share (1,624 underlying)
Exercise/Conversion
Restricted Share Unit
[F1][F7]
2026-04-01−1,750→ 3,500 total
→ Class A Ordinary Share (1,750 underlying)
Exercise/Conversion
Restricted Share Unit
[F1][F8]
2026-04-01−2,457→ 7,371 total
→ Class A Ordinary Share (2,457 underlying)

Footnotes (8)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F2]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026.
[F3]The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter.
[F4]Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee
[F5]Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply.
[F6]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023.
[F7]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024.
[F8]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025.

Signature

/s/ Douglas Barry, Attorney-in-Fact|2026-04-03

1 file